Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
SBHACat. No. 3810 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: N,N'-Dihydroxyoctanediamide |
Biological Activity
Histone deacetylase (HDAC) inhibitor (ID50 values are 0.25 and 0.3 μM for HDAC1 and HDAC3 respectively). Potentiates the cytostatic effects of 5-Fluorouracil (Cat. No. 3257) in colorectal cancer cells.Technical Data
M.Wt:The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
References
Richon et al (1998) A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc.Natl.Acad.Sci.U.S.A 95 3003. PMID: 9501205.
Brinkmann et al (2001) Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts. J.Biol.Chem. 276 22491. PMID: 11304533.
Zhang et al (2004) The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol.Cancer.Ther. 3 425. PMID: 15078986.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: SBHA, supplier, HDAC, inhibits, inhibitors, histone, deacetylases, induces, inducers, of, apoptosis, epigenetics
Quick Order
Find multiple products by catalog number
Cancer Research Guide
Request your free copy
Highlights over 350 products for cancer research. Request a copy or view PDF today.
Antidepressants - Current and Future Targets
Written by P. Skolnich et al
'Antidepressants - Current and Future Targets' provides an overview of the current and future targets for the treatment of major depressive disorder.
New Products in this Area
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.